MCM
CRVO icon

Manchester Capital Management’s CervoMed CRVO Stock Holding History

Manchester Capital Management’s Portfolio CRVO Stock Details CRVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-138
Closed -$2.36K – 1179
2024
Q2 		$2.36K Buy
+138
New +$3.02K ﹤0.01% 936

Other funds holding CRVO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Crown Advisors Management Larkspur, California $151M AUM 73.11% 1-Year Est. Return

Manchester Capital Management's CRVO Position: Q3 2024 in Review

Manchester Capital Management sold out of CervoMed (CRVO) in Q3 2024, closing a stake of 138 shares — an estimated $2.36K sold.

Manchester Capital Management first reported a position in CRVO in Q2 2024 and held it in 1 quarter. The position peaked at $2.36K in Q2 2024. 50 funds tracked by Wall St. Rank hold CRVO as of Q3 2024.

  • Manchester Capital Management reported no remaining CervoMed position as of Q3 2024 after selling out during the quarter.
  • Manchester Capital Management sold 138 CervoMed shares in Q3 2024, an estimated $2.36K.
  • Manchester Capital Management first reported a position in CervoMed in Q2 2024 and held it in 1 quarter.
  • Manchester Capital Management's CervoMed position peaked at $2.36K in Q2 2024.
  • 50 funds tracked by Wall St. Rank held CervoMed as of Q3 2024.

Based on Manchester Capital Management's 13F filing for Q3 2024, filed 5 Nov 2024.